Back to results
US 11,767,564 B2Granted
Use of SDHA as a prognostic marker and therapeutic target in uveal melanoma
AssigneeBoard of Regents, The University of Texas System
InventorsChandrani Chattopadhyay, Janos Roszik
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for identifying expression of SDHA, MIF, and or monosomy 3 or disomy 3 status in sample to identify the sample as high-risk melanoma and/or the sensitivity to oxidative phosphorylation inhibitors. Also provided herein are methods for treating monosomy 3 uveal melanoma by administering a SDHA inhibitor in combination with an oxidative phosphorylation inhibitor.
Claims18
A method of treating uveal melanoma in a human subject comprising:
- (a) determining the expression level of succinate dehydrogenase complex flavoprotein A (SDHA) in a sample from the subject;
- (b) identifying the subject as having Oxidative Phosphorylation (OXPHOS) resistant uveal melanoma by detecting elevated SDHA as compared to a control;
- and
- (c) administering an effective amount of an SDHA inhibitor in combination with an OXPHOS inhibitor to said subject to overcome resistance to the OXPHOS inhibitor.
1 more element
Dependencies are inferred from the claim text.